JP2024534707A - ４員縮合環式化合物、並びにその調製方法及び使用 - Google Patents
４員縮合環式化合物、並びにその調製方法及び使用 Download PDFInfo
- Publication number
- JP2024534707A JP2024534707A JP2024543428A JP2024543428A JP2024534707A JP 2024534707 A JP2024534707 A JP 2024534707A JP 2024543428 A JP2024543428 A JP 2024543428A JP 2024543428 A JP2024543428 A JP 2024543428A JP 2024534707 A JP2024534707 A JP 2024534707A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharma
- alkyl
- acceptable salt
- stereoisomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/22—Eight-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111161691.X | 2021-09-30 | ||
| CN202111161691 | 2021-09-30 | ||
| PCT/CN2022/122536 WO2023051681A1 (zh) | 2021-09-30 | 2022-09-29 | 四元稠环类化合物及其制备方法和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024534707A true JP2024534707A (ja) | 2024-09-20 |
| JP2024534707A5 JP2024534707A5 (https=) | 2025-10-07 |
Family
ID=85781355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024543428A Pending JP2024534707A (ja) | 2021-09-30 | 2022-09-29 | ４員縮合環式化合物、並びにその調製方法及び使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240400582A1 (https=) |
| EP (1) | EP4410779A4 (https=) |
| JP (1) | JP2024534707A (https=) |
| KR (1) | KR20240089224A (https=) |
| CN (1) | CN118139849A (https=) |
| AU (1) | AU2022355393A1 (https=) |
| CA (1) | CA3234312A1 (https=) |
| IL (1) | IL311791A (https=) |
| MX (1) | MX2024004025A (https=) |
| TW (1) | TW202330547A (https=) |
| WO (1) | WO2023051681A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ773110A (en) | 2018-09-18 | 2024-11-29 | Terns Inc | Compounds for treating certain leukemias |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0003476D0 (sv) * | 2000-09-28 | 2000-09-28 | Astrazeneca Ab | Compounds |
| CN103113355B (zh) * | 2013-02-27 | 2014-08-13 | 无锡爱内特生物科技有限公司 | 一种Bcr/Abl酪氨酸激酶抑制剂及其制备方法和在治疗慢性粒细胞白血病中的应用 |
| CN109790144A (zh) * | 2016-04-29 | 2019-05-21 | 爱仕达生物技术有限责任公司 | 新型杂环化合物作为酪氨酸激酶bcr-abl抑制剂 |
| US11649218B2 (en) * | 2018-03-09 | 2023-05-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | C-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same |
-
2022
- 2022-09-29 EP EP22875063.4A patent/EP4410779A4/en active Pending
- 2022-09-29 MX MX2024004025A patent/MX2024004025A/es unknown
- 2022-09-29 WO PCT/CN2022/122536 patent/WO2023051681A1/zh not_active Ceased
- 2022-09-29 US US18/697,312 patent/US20240400582A1/en active Pending
- 2022-09-29 KR KR1020247014535A patent/KR20240089224A/ko active Pending
- 2022-09-29 IL IL311791A patent/IL311791A/en unknown
- 2022-09-29 CA CA3234312A patent/CA3234312A1/en active Pending
- 2022-09-29 CN CN202280064600.7A patent/CN118139849A/zh active Pending
- 2022-09-29 AU AU2022355393A patent/AU2022355393A1/en active Pending
- 2022-09-29 JP JP2024543428A patent/JP2024534707A/ja active Pending
- 2022-09-30 TW TW111137341A patent/TW202330547A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024004025A (es) | 2024-05-31 |
| EP4410779A4 (en) | 2025-07-30 |
| TW202330547A (zh) | 2023-08-01 |
| CN118139849A (zh) | 2024-06-04 |
| IL311791A (en) | 2024-05-01 |
| WO2023051681A1 (zh) | 2023-04-06 |
| AU2022355393A1 (en) | 2024-05-09 |
| CA3234312A1 (en) | 2023-04-06 |
| US20240400582A1 (en) | 2024-12-05 |
| EP4410779A1 (en) | 2024-08-07 |
| KR20240089224A (ko) | 2024-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI765908B (zh) | 苯並咪唑類化合物激酶抑制劑及其製備方法和應用 | |
| CN113214287B (zh) | Hpk1抑制剂及其使用方法 | |
| KR102374012B1 (ko) | N-(아자릴)시클로락탐-1-카르복사미드 유도체 및 합성법과 그 용법 | |
| JP5976826B2 (ja) | Ｂｔｋ活性阻害剤としての８−フルオロフタラジン−１（２ｈ）−オン化合物 | |
| US11767296B2 (en) | Heteroaryl compounds as kinase inhibitor | |
| CN113348170B (zh) | 联苯类衍生物抑制剂、其制备方法和应用 | |
| CN112292378B (zh) | 含吲哚类衍生物抑制剂、其制备方法和应用 | |
| JP6339241B2 (ja) | Ａｌｋキナーゼ阻害剤並びにその調製方法及び使用 | |
| TW202317564A (zh) | Cdk2抑制劑及其製備方法和用途 | |
| ES2289004T3 (es) | Nuevos compuestos. | |
| EA007063B1 (ru) | ПРОИЗВОДНЫЕ АМИНОБЕНЗАМИДОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ГЛИКОГЕНСИНТАЗА-КИНАЗЫ 3β; | |
| BR112015020772B1 (pt) | Compostos de pirimidina e piridina e seu uso | |
| KR20240144965A (ko) | 단백질 티로신 포스파타제의 억제제, 조성물 및 사용 방법 | |
| JP2021536436A (ja) | キノリン誘導体から調製される新規な阻害剤 | |
| TW201835079A (zh) | ６－吡唑－［１，２，４］三唑並［４，３－α］吡啶－３－醯胺類衍生物、其製備方法及其在醫藥上的應用 | |
| JP2024534707A (ja) | ４員縮合環式化合物、並びにその調製方法及び使用 | |
| CN108779100A (zh) | 3,4-二吡啶基吡唑类衍生物、其制备方法及其在医药上的应用 | |
| KR20210019510A (ko) | Fgfr억제제, 그 제조 방법 및 용도 | |
| TW202136259A (zh) | 聯苯類衍生物抑制劑及其製備方法和應用 | |
| CN120535516A (zh) | 一种POLθ抑制剂及其用途 | |
| TW202241862A (zh) | 二甲醯胺類化合物、其製備方法及其在醫藥上的應用 | |
| HK1261495A1 (en) | 3,4-bipyridyl pyrazole derivative, and preparation method therefor and medical application thereof | |
| HK40003421B (en) | Benzimidazole compound kinase inhibitor, preparation method therefor and application thereof | |
| HK40003421A (en) | Benzimidazole compound kinase inhibitor, preparation method therefor and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250926 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250926 |